Our results showed that ZGGS15 can competitively inhibit the binding of LAG-3 with MHC-II and the binding of TIGIT with CD155, supporting the potential clinical applications of ZGGS15 in cancer patients with high FGL1 expression (e.g., hepatocellular carcinoma)56. The gene discussed is PVR; the disease is cancer.